Clinical Trials Logo

Cytomegalovirus (CMV) Infection clinical trials

View clinical trials related to Cytomegalovirus (CMV) Infection.

Filter by:
  • None
  • Page 1

NCT ID: NCT03940586 Completed - Clinical trials for Cytomegalovirus (CMV) Infection

Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)

Start date: August 8, 2019
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the pharmacokinetics (PK) of letermovir (LET) in pediatric participants. Participants will be enrolled in the following 3 age groups: Age Group 1: From 12 to <18 years of age (adolescents); Age Group 2: From 2 to <12 years of age (children); and Age Group 3: From birth to <2 years of age (neonates, infants and toddlers). All participants will receive open label LET for 14 weeks (~100 days) post-transplant, with doses based on body weight and age.

NCT ID: NCT03629080 Completed - Clinical trials for Kidney Transplantation

A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients

Start date: December 12, 2018
Phase: Phase 2
Study type: Interventional

HB-101 is a bivalent recombinant vaccine against human CMV infection. This is a randomized, placebo-controlled, phase 2 study to assess the safety, reactogenicity, immunogenicity, and efficacy of HB-101 in CMV-Seronegative patients receiving a kidney transplant from a CMV-Seropositive living donor and CMV-Seropositive patients.Patients enrolled should have a living donor kidney transplantation ideally planned between two to four months after the first injection of study drug (HB-101 or placebo).

NCT ID: NCT01651585 Completed - Foetuses Infection Clinical Trials

In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir

CYMEVAL2
Start date: July 2011
Phase: Phase 4
Study type: Interventional

The infection with cytomegalovirus (CMV) is the first cause of congenital neurological handicap of infectious origin. It is probable that the néonatale viral load is correlated with becoming of infected new-born babies. Among the active antiviral treatments against CMV, valacyclovir is the only whose fœtal and maternal tolerance was evaluated during the pregnancy. Its harmlessness and its aptitude to decrease the CMV viral load justify to evaluate it in a study. Decrease the fœtal viral load could make possible to decrease symptomatology néonatale in a group of infected fœtuses.